07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

A/H7N9 Influenza Rapid Test regulatory update

FDA granted Emergency Use Authorization (EUA) for Arbor Vita’s A/H7N9 Influenza Rapid Test for the presumptive detection of influenza A subtype H7N9 in patients with signs and symptoms of respiratory infection in conjunction with epidemiological...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

HPV E6 test: Interim data

Interim data from 3,179 evaluable women in the Chinese START-UP trial showed that Arbor Vita's HPV E6 Test had 99% specificity and 69.6% sensitivity for detecting CIN3+ precancerous lesions. Comparatively, visual inspection of the cervix...
00:58 , Sep 20, 2011 |  BC Extra  |  Clinical News

Arbor Vita reports HPV test data

Arbor Vita Corp. (Fremont, Calif.) said its HPV E6 Test had 99% specificity and 69.6% sensitivity for detecting CIN3+ precancerous lesions in a trial to diagnose cervical cancer and cervical intraepitheleal neoplasia (CIN) precancerous lesions....
07:00 , Apr 13, 2009 |  BC Week In Review  |  Clinical News

AVantage A/H5N1 Flu Test regulatory update

FDA granted 510(k) clearance for Arbor Vita's AVantage A/H5N1 Flu Test to detect H5N1 avian influenza A virus. The company plans to launch the diagnostic, which detects influenza virus non-structural protein 1 (NS-1) from nose...
08:00 , Nov 17, 2008 |  BC Week In Review  |  Company News

Arbor Vita, Becton Dickinson deal

The companies will co-develop a diagnostic for cervical cancer that uses Arbor Vita's PDZ protein technology to detect the transforming protein E6, an HPV oncoprotein associated with progression of HPV to cervical cancer. Further terms...
07:00 , Mar 31, 2008 |  BC Week In Review  |  Clinical News

AVC Dx-2: Preliminary pilot trial data

Preliminary data showed that the company’s rapid H5N1 flu antigen assay test identified 0 false positives against a clinical panel of 28 isolates from avian and human sources. Of the 28 H5N1 cultures tested, 26...